Neuren Pharmaceuticals Ltd
ASX:NEU
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
AU |
|
Harvest Gold Corp
XTSX:HVG
|
CA |
|
G
|
Gentili Mosconi SpA
MIL:GM
|
IT |
|
IHH Healthcare Bhd
OTC:IHHHF
|
MY |
|
Ace Hardware Indonesia Tbk PT
OTC:ACEHF
|
ID |
|
Ariana Resources PLC
LSE:AAU
|
UK |
|
DRDGOLD Ltd
NYSE:DRD
|
ZA |
|
D
|
Dechra Pharmaceuticals PLC
F:1PK
|
UK |
|
V
|
VinFast Auto Ltd
NASDAQ:VFS
|
SG |
|
United Therapeutics Corp
NASDAQ:UTHR
|
US |
|
Scholastic Corp
NASDAQ:SCHL
|
US |
Wall St Price Targets
NEU Price Targets Summary
Neuren Pharmaceuticals Ltd
According to Wall Street analysts, the average 1-year price target for NEU is 23.92 AUD with a low forecast of 18.79 AUD and a high forecast of 30.45 AUD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is NEU's stock price target?
Price Target
23.92
AUD
According to Wall Street analysts, the average 1-year price target for NEU is 23.92 AUD with a low forecast of 18.79 AUD and a high forecast of 30.45 AUD.
What is the Revenue forecast for Neuren Pharmaceuticals Ltd?
Projected CAGR
38%
Over the last 14 years, the compound annual growth rate for Revenue has been 25%. The projected CAGR for the next 3 years is 38%.
What is the Operating Income forecast for Neuren Pharmaceuticals Ltd?
Projected CAGR
132%
The compound annual growth rate for Operating Income over the next 4 years is 132%.
What is the Net Income forecast for Neuren Pharmaceuticals Ltd?
Projected CAGR
117%
The compound annual growth rate for Net Income over the next 4 years is 117%.
